Ligand Pharmaceuticals | LGND - Sales Revenues


Ligand Pharmaceuticals reported $59.66M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agenus USD 24.07M 2.77M Mar/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 26.17M 12.58M Mar/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Enviri Corporation USD 2.34B 1.77B Dec/2024
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Insmed USD 263.8M 121.8M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 140.6M 8.7M Dec/2025